A well-known complement inhibitor is eculizumab , which targets C5, a protein in the terminal complement pathway. By blocking C5, eculizumab prevents the formation of the MAC and reduces the risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback